Find Uttroside B manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Qk6vn86e3t, 88048-09-3, Unii-qk6vn86e3t, Chembl499185, .beta.-d-galactopyranoside, (3.beta.,5.alpha.,22.alpha.,25r)-26-(.beta.-d-glucopyranosyloxy)-22-hydroxyfurostan-3-yl o-.beta.-d-glucopyranosyl-(1->2)-o-(.beta.-d-xylopyranosyl-(1->3))-o-.beta.-d-glucopyranosyl-(1->4)-, Beta-d-galactopyranoside, (3beta,5alpha,22alpha,25r)-26-(beta-d-glucopyranosyloxy)-22-hydroxyfurostan-3-yl o-beta-d-glucopyranosyl-(1->2)-o-(beta-d-xylopyranosyl-(1->3))-o-beta-d-glucopyranosyl-(1->4)-
Molecular Formula
C56H94O28
Molecular Weight
1215.3  g/mol
InChI Key
FJLUJBDSFBGOPL-YOKUEUOXSA-N
FDA UNII
QK6VN86E3T

Uttroside B
(2S,3R,4S,5S,6R)-2-{[(2S,3R,4S,5R,6R)-2-{[(2R,3R,4R,5R,6R)-4,5-dihydroxy-6-{[(1R,2S,4S,6R,7S,8R,9S,12S,13S,16S,18S)-6-hydroxy-7,9,13-trimethyl-6-[(3R)-3-methyl-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-5-oxapentacyclo[10.8.0.0,.0,.0,]icosan-16-yl]oxy}-2-(hydroxymethyl)oxan-3-yl]oxy}-5-hydroxy-6-(hydroxymethyl)-4-{[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol is a natural product found in Solanum americanum, Capsicum annuum var. annuum, and other organisms with data available.
1 2D Structure

Uttroside B

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2R,3R,4S,5S,6R)-2-[(2R)-4-[(1R,2S,4S,6R,7S,8R,9S,12S,13S,16S,18S)-16-[(2R,3R,4R,5R,6R)-3,4-dihydroxy-5-[(2S,3R,4S,5R,6R)-5-hydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosan-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
2.1.2 InChI
InChI=1S/C56H94O28/c1-21(19-74-49-43(70)39(66)36(63)30(15-57)77-49)7-12-56(73)22(2)34-29(84-56)14-27-25-6-5-23-13-24(8-10-54(23,3)26(25)9-11-55(27,34)4)76-51-45(72)41(68)46(33(18-60)80-51)81-53-48(83-52-44(71)40(67)37(64)31(16-58)78-52)47(38(65)32(17-59)79-53)82-50-42(69)35(62)28(61)20-75-50/h21-53,57-73H,5-20H2,1-4H3/t21-,22+,23+,24+,25-,26+,27+,28-,29+,30-,31-,32-,33-,34+,35+,36-,37-,38-,39+,40+,41-,42-,43-,44-,45-,46+,47+,48-,49-,50+,51-,52+,53+,54+,55+,56-/m1/s1
2.1.3 InChI Key
FJLUJBDSFBGOPL-YOKUEUOXSA-N
2.1.4 Canonical SMILES
CC1C2C(CC3C2(CCC4C3CCC5C4(CCC(C5)OC6C(C(C(C(O6)CO)OC7C(C(C(C(O7)CO)O)OC8C(C(C(CO8)O)O)O)OC9C(C(C(C(O9)CO)O)O)O)O)O)C)C)OC1(CCC(C)COC1C(C(C(C(O1)CO)O)O)O)O
2.1.5 Isomeric SMILES
C[C@H]1[C@H]2[C@H](C[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@@H]5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O)C)C)O[C@@]1(CC[C@@H](C)CO[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O
2.2 Other Identifiers
2.2.1 UNII
QK6VN86E3T
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Qk6vn86e3t

2. 88048-09-3

3. Unii-qk6vn86e3t

4. Chembl499185

5. .beta.-d-galactopyranoside, (3.beta.,5.alpha.,22.alpha.,25r)-26-(.beta.-d-glucopyranosyloxy)-22-hydroxyfurostan-3-yl O-.beta.-d-glucopyranosyl-(1->2)-o-(.beta.-d-xylopyranosyl-(1->3))-o-.beta.-d-glucopyranosyl-(1->4)-

6. Beta-d-galactopyranoside, (3beta,5alpha,22alpha,25r)-26-(beta-d-glucopyranosyloxy)-22-hydroxyfurostan-3-yl O-beta-d-glucopyranosyl-(1->2)-o-(beta-d-xylopyranosyl-(1->3))-o-beta-d-glucopyranosyl-(1->4)-

2.4 Create Date
2010-01-26
3 Chemical and Physical Properties
Molecular Weight 1215.3 g/mol
Molecular Formula C56H94O28
XLogP3-3
Hydrogen Bond Donor Count17
Hydrogen Bond Acceptor Count28
Rotatable Bond Count18
Exact Mass1214.59316234 g/mol
Monoisotopic Mass1214.59316234 g/mol
Topological Polar Surface Area445 Ų
Heavy Atom Count84
Formal Charge0
Complexity2140
Isotope Atom Count0
Defined Atom Stereocenter Count36
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

Present study attests to previous report that Uttroside-B is pharmacologically safe up to five times IC50 dose in acute and sub-chronic toxicity models, while even IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib adverse effects.


Lead Product(s): Uttroside B

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: PreclinicalProduct Type: Small molecule

Sponsor: Oklahoma Medical Research Foundation

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 26, 2022

blank

01

Q BioMed

U.S.A
arrow
BioFlorida Conference
Not Confirmed

Q BioMed

U.S.A
arrow
BioFlorida Conference
Not Confirmed

Lead Product(s) : Uttroside B

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Partner/Sponsor/Collaborator : Oklahoma Medical Research Foundation

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Present study attests to previous report that Uttroside-B is pharmacologically safe up to five times IC50 dose in acute and sub-chronic toxicity models, while even IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib...

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 26, 2022

blank

Details:

In the initial Scientific Reports study, researchers showed that in animal models, Uttroside-B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the FDA for liver cancer approved at the time.


Lead Product(s): Uttroside B

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: PreclinicalProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2022

blank

02

Q BioMed

U.S.A
arrow
BioFlorida Conference
Not Confirmed

Q BioMed

U.S.A
arrow
BioFlorida Conference
Not Confirmed

Details : In the initial Scientific Reports study, researchers showed that in animal models, Uttroside-B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the FDA for liver cancer approved at the time.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 16, 2022

blank

Details:

The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC).


Lead Product(s): Uttroside B

Therapeutic Area: Oncology Brand Name: Uttroside-B

Study Phase: PreclinicalProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 26, 2021

blank

03

Q BioMed

U.S.A
arrow
BioFlorida Conference
Not Confirmed

Q BioMed

U.S.A
arrow
BioFlorida Conference
Not Confirmed

Details : The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC).

Brand Name : Uttroside-B

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 26, 2021

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty